Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.

Paul Brear, Darby Ball, Katherine Stott, Sheena D'Arcy, Marko Hyvönen

Journal of medicinal chemistry 2020 Nov 12

filter terms:

CK2α is a ubiquitous, well-studied kinase that is a target for small-molecule inhibition, for treatment of cancers. While many different classes of adenosine 5'-triphosphate (ATP)-competitive inhibitors have been described for CK2α, they tend to suffer from significant off-target activity and new approaches are needed. A series of inhibitors of CK2α has recently been described as allosteric, acting at a previously unidentified binding site. Given the similarity of these inhibitors to known ATP-competitive inhibitors, we have investigated them further. In our thorough structural and biophysical analyses, we have found no evidence that these inhibitors bind to the proposed allosteric site. Rather, we report crystal structures, competitive isothermal titration calorimetry (ITC) and NMR, hydrogen-deuterium exchange (HDX) mass spectrometry, and chemoinformatic analyses that all point to these compounds binding in the ATP pocket. Comparisons of our results and experimental approach with the data presented in the original report suggest that the primary reason for the disparity is nonspecific inhibition by aggregation.

Citation

Paul Brear, Darby Ball, Katherine Stott, Sheena D'Arcy, Marko Hyvönen. Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α. Journal of medicinal chemistry. 2020 Nov 12;63(21):12786-12798